Ad­vi­so­ry com­mit­tee votes aren't go­ing away with in­com­ing re­forms, FDA of­fi­cials say

WASH­ING­TON — Two top lead­ers from the FDA said changes to the agency’s ad­vi­so­ry com­mit­tee process won’t elim­i­nate the up-or-down votes whose ne­ces­si­ty Com­mis­sion­er Rob Califf has ques­tioned in re­cent months.

The goal of the com­ing ad­comm re­forms is to make the process as ef­fi­cient as pos­si­ble, Pe­ter Stein, di­rec­tor of the FDA’s Of­fice of New Drugs, ex­plained to the Bio­phar­ma Con­gress in Wash­ing­ton on Mon­day. That in­cludes stan­dard­iz­ing de­ci­sion-mak­ing for when to hold the ad­vi­so­ry meet­ings, Stein said, and bring­ing more con­sis­ten­cy to how dif­fer­ent agency cen­ters and di­vi­sions con­duct the dis­cus­sions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER